XASX
BP8
Market cap1mUSD
Sep 17, Last price
0.01AUD
1D
10.00%
1Q
-45.00%
IPO
-100.00%
Name
Stemcell United Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.38%
Rev. gr., 5y
-16.52%
Revenues
3m
+877.51%
Net income
-2m
L+20.27%
CFO
-2m
L+129.67%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BPH Global Ltd, along with its associated entities, specializes in the procurement, production, promotion, and sale of traditional medicinal items. Its operational reach spans Australia, Singapore, China, and the broader Southeast Asian market. The company's diverse product range features both unprocessed and refined bird's nest offerings, alongside marine botanicals like Caulerpa Lentillifera (sea grapes) and various seaweeds. These products are utilized across multiple industries, including food, nutrition, healthcare, dietary supplements, cosmetics, and personal care. Headquartered in Melbourne, Australia, the company was founded in 1984 and transitioned to its current name, BPH Global Ltd, in June 2023, having previously been known as Stemcell United Limited.
Key people
Chow-Yee Koh
Joint Company Secretary, Director · since 2014
Glenn Davies
Director · since 2018
Huan Qing Gu
Director · since 2015
Philip Gu
Chairman of the Board, Chief Executive Officer, Managing Director
Yanhua Huang
Non-Executive Director · since 2019
Legal address
COMPANY MATTERS PTY LIMITED
LEVEL 12
680 GEORGE STREET
SYDNEY, NSW 2000
AU
LEVEL 12
680 GEORGE STREET
SYDNEY, NSW 2000
AU
Headquarters
43 GURRS ROAD
BEULAH PARK, SA 5067
AU
BEULAH PARK, SA 5067
AU
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT |